When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Before Congress adjourned for Christmas, congressional leadership had set ambitious goals to counter the Chinese Communist ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

The transaction – announced on Christmas Eve – comes after WuXi AppTec has been thrust into the US political spotlight as a ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...

2024 was eventful in the life sciences space – and key trends are expected to continue in the new year. Below, we outline key areas to watch in 2025. In recent years, several trends have heightened ...

In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey ...

A summary of recent health news includes Louisiana's first bird flu death, WuXi Biologics' sale of an Irish facility to Merck ...

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...

Market capitalization of the largest public biotech companies jumps nearly 12% year-over-year, as all but five of them show ...

WUXI Biologics Cayman will sell a vaccine facility in Ireland to Merck for about US$500 million as the Chinese company seeks ...